News of Note—AstraZeneca’s FluMist, Dynavax’s Heplisav-B head to ACIP, and more

non
In this week's news of note, AstraZeneca's FluMist and Dynavax's Heplisav-B present in front of a CDC panel. (Pixabay)

Here is some other vaccine news of note for the week.

> AstraZeneca’s FluMist, hoping to make a comeback after being struck down for two flu seasons, and Dynavax’s Heplisav-B, aiming to challenge GlaxoSmithKline’s Engerix-B, are both under consideration at a CDC panel today. Meeting schedule

> A new bill proposed by Sen. Richard Blumenthal, D-Conn., Ed Markey, D-Mass., and several other fellow senators calls for $1 billion over the next five years for development of a universal flu vaccine. Associated Press story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.

> Preclinical data published in the journal Vaccine showed Moderna’s mRNA vaccine platform might work to develop vaccines to prevent human cytomegalovirus. Release

> The Khushi Baby system, which includes a necklace with a computer chip that stores up to two years of vaccination records for young children, won the grand prize from Johnson & Johnson’s GenH Challenge for Maternal and Child Health. Release